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Abstract
Objective—To determine the time between first intercourse and first sexually transmitted
infection (STI) with Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis
and time between repeated infections.
Design—Observational study.
Setting—Three adolescent medicine clinics.
Participants—A cohort of 386 urban young women aged 14 to 17 years at enrollment.
Main Outcome Measures—Age at first intercourse; organism-specific interval between first
intercourse and first STI diagnosis; interval between repeated infections; and age at first STI test
prior to study participation.
Results—Participants had first intercourse at a young age (first, second, and third quartiles were
13, 14, and 15 years of age, respectively). By age 15 years, 25% of the women acquired their first
STI, most often C trachomatis. Median interval between first intercourse and first STI diagnosis
was 2 years. Within 1 year of first intercourse, 25% had their first C trachomatis infection.
Repeated infections were common; within 3.6, 6, and 4.8 months, 25% of the women with prior C
trachomatis, N gonorrhoeae, and T vaginalis infection were reinfected with the respective
organisms. Considerable delay in STI testing was found for those who began sex at a younger age.
The median interval between first sex and first test were 4.9, 3.5, 2.1, 1.8, and 1.2 years for those
who had first sex at ages 10, 11, 12, 13, and 14 years, respectively.
Conclusions—Timely screening and treatment are important for prevention of STI sequelae.
For urban adolescent women, STI screening (especially for C trachomatis) should begin within a
year after first intercourse and infected individuals should be retested every 3 to 4 months.
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Screening adolescent women for selected sexually transmitted infections (STIs)—by sexual
history to identify risk and by laboratory testing to verify infection—is endorsed by clinical
practice guidelines and implemented in at least some proportion of health visits for
adolescents.1–3 Sexually transmitted infection screening is justified by disproportionate STI
morbidity among young women, including pelvic inflammatory disease, ectopic pregnancy,
tubal infertility, preterm birth, and increased susceptibility to human immunodeficiency
virus infection.3–11
The 2006 Sexually Transmitted Diseases Treatment Guidelines recommend Chlamydia
screening for women younger than 26 years but do not suggest a beginning age for such
screening.12 Similarly, the US Preventive Services Task Force makes no recommendations
about the beginning age of STI screening and periodicity of screening because of limitations
of epidemiological data.13,14 These limitations include relatively short follow-up periods,
infrequent testing schedules, and the inability to reliably ascertain infection outside the
observational period and study venues. A clearly delineated timeline of major events related
to STI acquisition in the life of young women would provide a basis for more effective STI
screening strategies. Additionally, such data could shed new light on the natural history of
STI during adolescence and young adulthood.
Herein, we used data from a longitudinal study in combination with participants’ medical
records. The combined data offered a unique opportunity to reconstruct infection histories in
a group of inner-city young women. We addressed 3 questions about the timing of STI-
related events. First, what is the interval between a young woman’s first sexual intercourse
and her first Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis
infection? Answers to this question could better guide decisions about the appropriate timing
of first STI screening. Second, what is the interval between first and subsequent infections
by C trachomatis, N gonorrhoeae, or T vaginalis? Better understanding of this interval
would provide information as to the most appropriate screening frequency as well as the
duration of such screening in adolescence. Finally, what is the relationship between the age
at first coitus and age at first STI test prior to enrollment in our study? Defining this
relationship can help determine if risk ascertainment and provider testing behavior vary by
age.
METHODS
STUDY DESIGN
This analysis is based on a convenience sample of young women enrolled in a longitudinal
study of factors related to STI, referred to as the Young Women’s Project (YWP).
Enrollment started in 1999, with maximal length of follow-up approaching 8.2 years (2995
days). The research was approved by the institutional review board of Indiana University–
Purdue University at Indianapolis.
Enrollment—Young women between the ages of 14 and 17 years, able to understand
English, without serious psychiatric diagnoses or substance use disorder and attending 1 of 3
adolescent medicine clinics were eligible for enrollment. The 3 adolescent medicine clinics
primarily serve the inner-city population of Indianapolis. Young women were identified by
clinic schedule and those who agreed to participate were enrolled at the current or
subsequent clinical visit. Young women were enrolled without regard to sexual experience.
Participants’ written informed consent and written parental permission were obtained at
enrollment.
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At enrollment, participants completed a self-administered questionnaire and a face-to-face
interview with trained research associates to establish lifetime and recent (past 3 months)
sexual behaviors, as well as lifetime STI history. Cervical and vaginal specimens were
collected by a research nurse practitioner.
Follow-up—Participants returned for follow-up every 3 months. At each 3-month visit,
participants completed face-to-face interviews to establish sexual behaviors in the previous 3
months. Participants had high completion rates for quarterly interviews, with only 5% of
possible follow-up interviews missing. The self-administered questionnaire was repeated
annually. Cervical and vaginal specimens were obtained for STI testing every 3 months.
In alternating quarters, study participants were instructed to complete daily behavioral
diaries and submit weekly self-administered vaginal swabs for STI testing. Self-
administered vaginal swabs have shown high acceptability and excellent sensitivity and
specificity.15 Vaginal swab samples were retrieved by study personnel each week. Samples
were stored at −20°C and processed in batches and test results were made available to study
personnel just before each participant’s subsequent quarterly visit, at which time infected
participants were treated.16 Study participants were compensated $2 for each completed
diary and $5 for each cervicovaginal specimen.
ASCERTAINMENT OF DEMOGRAPHIC AND SEXUAL BEHAVIORAL INFORMATION
Demographic and sexual behavioral information was ascertained from the interviews and
diaries. At each interview, participants were asked about lifetime and past 3 months’
experiences of vaginal, oral, and anal sex; lifetime and past 3 months’ sexual partners; and
intercourse frequency and condom use in the past 3 months. Age at first sexual intercourse
and lifetime history of STI were obtained at enrollment and annually.
The age at first sexual intercourse was primarily established by self-report provided during
the face-to-face interview at enrollment. To establish the reliability of such self-reports, we
compared age at first sex reported at enrollment with that reported 1 year later. This analysis
showed 94.0% agreement within 1 year. For participants without lifetime intercourse
experience at enrollment, age at first sex was determined from follow-up interviews and
diaries.
STI TESTING AND DETERMINATION OF INFECTION EPISODES
Nucleic acid amplification tests (NAATs) were used to analyze all study specimens for C
trachomatis and N gonorrhoeae (Amplicor CT/NG PCR; Roche Diagnostics, Indianapolis).
Detection of T vaginalis DNA was performed using a modification of the Amplicor CT/NG
PCR assay that included primers and probes specific for T vaginalis.17
The following decision rule was used to identify infections in this repetitively tested cohort.
First, positive test results for C trachomatis, N gonorrhoeae, or T vaginalis obtained from
participants’ medical records were considered as true infection episodes. Positive test results
based on cervical swab samples conducted at quarterly clinical visits were also considered as
true infection episodes, as consistent with current practice. In the absence of quarterly test
results, we used weekly vaginal samples to determine the presence of C trachomatis or T
vaginalis. For weekly samples, we required at least 3 positive NAAT results to avoid
misinterpreting transient DNA deposited during recent coitus as new infection.18 We also
required that these positive test results be at least 3 weeks after treatment of a previous
infection to avoid misinterpreting transient DNA shedding following successful treatment as
a new infection.16,18 Because of false-positive NAAT results for N gonorrhoeae,19 samples
Tu et al. Page 3
Arch Pediatr Adolesc Med. Author manuscript; available in PMC 2011 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
testing positive by the Amplicor CT/NG PCR were confirmed by Gen-Probe (San Diego,
California) Aptima, which amplifies a different molecular target.16,18,20
DATA OBTAINED FROM PARTICIPANTS’ MEDICAL RECORDS
To reduce potential bias due to failure to identify sexual behavior and STI diagnosed before
or outside of study participation, we examined the participants’ medical records for test
results for C trachomatis, N gonorrhoeae, and T vaginalis. Medical records were searched
with the aid of the Regenstrief Medical Record System (Regenstrief Institute, Inc,
Indianapolis).The Regenstrief Medical Record System is a comprehensive electronic
medical record system that links most major regional hospitals located in Indianapolis,
including all primary care and acute care facilities affiliated with Wishard Health Services,
to which the study sites belong. Additionally, we extracted and incorporated study
participants’ test and treatment data from the county sexually transmitted disease clinic.
Together, these clinics represent nearly all nonprivate STI testing facilities in the greater
Indianapolis metropolitan area. Sexually transmitted infection testing methods were
heterogeneous, including culture-based diagnostics (approximately 10% of diagnoses) and
DNA amplification tests (about90% of diagnoses) for C trachomatis and N gonorrhoeae.
For T vaginalis, diagnoses were made by wet preparation microscopy (17%) and NAAT
(83%). The high rates of NAAT diagnosis, especially for T vaginalis, reflected the fact that
all research test results from the study laboratory, which were based on amplification
methods, were incorporated into the Regenstrief Medical Record System. The medical
record data were extracted on April 27, 2008.
DOCUMENTATION OF TREATMENT
At enrollment and quarterly follow-up visits, STI test results were provided to research and
clinic staff within 72 hours of sample collection. Treatment according to published
guidelines was provided, typically within 1 week of testing. Infections identified from
samples collected during the weekly vaginal sampling periods were treated at the end of
each 3-month period. The antibiotic types and regimen details were recorded for each
treatment. To identify potentially effective treatments occurring outside of study
participation, all prescription antibiotic orders were extracted from participants’ medical
records in the Regenstrief Medical Record System. Antibiotics were considered effective for
a given STI if listed in the 2006 Sexually Transmitted Diseases Treatment Guidelines.12
Antibiotic regimens not listed in the treatment guidelines were considered effective on the
basis of published data documenting activity or cure of at least 80% for the STI in question.
21,22 More than 96% of relevant treatments offered and documented by our study were
consistent with guidelines.
DATA ANALYSIS
Demographic, behavioral, and clinical characteristics of study participants were summarized
and reported in tabular form. First intercourse was the event of interest. Age at first
intercourse was ascertained from the enrollment interview if the participant had been
sexually active prior to study enrollment or from subsequent quarterly interviews or diaries
if she had become sexually active during the study. Age at first sex for participants who had
reported no intercourse either before or during the study was censored at the last study visit.
The distribution of age at first sex was depicted by a Kaplan-Meier curve.23 We also used
survival analyses to examine the time between the first sexual intercourse and the first
diagnosis with C trachomatis, N gonorrhoeae, or T vaginalis infection. In this analysis, the
events of interest were the first documented infections with each of the 3 organisms. The
event times were censored at the last visit time if no infection was documented during the
observation period. Selected quartiles (25th and 50th percentiles) of the event times were
obtained and results reported in tabular form. Using similar techniques, we reported the
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interval from first to next infection as well as intervals between subsequent infections.
Similarly, we examined the age distributions of the first infection with each of the 3
organisms.24
Finally, we examined the timing of first STI test in relationship to the age at first
intercourse. Because the test results obtained after study enrollment reflect study procedures
instead of normal clinical STI testing behavior, we only used data from participants who had
received STI tests as documented in their medical records prior to enrollment; participants
who had received no STI tests before study participation were censored at enrollment. A
scatterplot was used to present the relationship between the age at the first coitus and age at
first STI test; different symbols were used to differentiate the observed non-study STI tests
from the censored observations.
Descriptive and survival analyses were implemented using SAS25 and all figures were made
using Splus (Insightful Corporation, Seattle, Washington).
RESULTS
Baseline demographic, behavioral, and clinical characteristics of the 386 study participants
measured at the time of enrollment are summarized in Table 1. Study participants reported
an average of 3 partners in their lifetime (median, 2; range, 0–28) at enrollment. Three
hundred sixty-four of the 386 participants (94%) reported first sexualinter course prior to
completing the study. Among the 364 sexually active women, 285 (78.3%) reported sexual
intercourse prior to study enrollment and 79 (21.7%) became sexually active during the
follow-up period. Age distribution of first sexual intercourse is shown in the Figure, A.
The average number of sexual partners in the 2 months prior to enrollment was 1 (median, 1;
range, 0–10). Based on extracted medical record data, 147 (51.6%) of the 285 sexually
experienced participants had 1 or more laboratory-documented C trachomatis (41.4%), N
gonorrhoeae (14.0%), or T vaginalis (13.7%) infections prior to enrollment (Table 2). Self-
reported STI history data were in agreement with the medical records. Of the 285 sexually
experienced participants, 44% reported at least 1 STI prior to YWP enrollment; 37.2%,
15.8%, and 16.1% of these women reported prior C trachomatis, N gonorrhoeae, or T
vaginalis infections.
The interval between first sexual intercourse and first STI diagnosis was examined by
Kaplan-Meier estimates of the proportion of participants without C trachomatis, N
gonorrhoeae, or T vaginalis infections (Figure, B). C trachomatis infections were identified
significantly sooner than either N gonorrhoeae or T vaginalis infections. The median times
between first sexual intercourse and first C trachomatis, N gonorrhoeae, or T vaginalis
infections were 3, 5, and 6 years, respectively. A similar pattern was seen when time to first
STI was examined as a function of chronologic age. The median ages of the first C
trachomatis, N gonorrhoeae, or T vaginalis infection were 17 years, 19 years, and 19 years,
respectively. However, the median age of the first STI of any type was 16 years. The median
length of infection-free interval following first sexual intercourse was only 2 years.
The intervals between the initial STI and first reinfection are shown in the Figure, C. Median
time to first reinfection was 1.2 years (426 days). Median time to the first C trachomatis
reinfection was about 1.6 years (581 days), with about 36% of these infections occurring in
the first year. The median time to the first N gonorrhoeae reinfection was about 2.4 years
(878 days), with 26% occurring in the first year following initial diagnosis of gonorrhea.
Median time to the first T vaginalis reinfection was about 1.7 years (616 days). Within 2
years, about 75% of participants with an initial STI were diagnosed with a second STI, not
necessarily of the same type. Within 4 years of an initial STI, virtually all (92%) of the
Tu et al. Page 5
Arch Pediatr Adolesc Med. Author manuscript; available in PMC 2011 January 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
participants had a second STI. When all repeated STIs were taken into account, intervals
between infections were even shorter (Table 2). The shorter intervals between later
infections as opposed to first infections possibly reflect the increased frequency of testing
during the study period compared with the pre-study period.
According to the extracted medical records, 283 of the 386 participants (73%) had received
STI tests prior to YWP enrollment. The median age at first STI test received before YWP
enrollment was 15 years (mean, 15.4 years), approximately 1 year after the median age of
first sexual intercourse. Closer examination revealed that age at first STI test was not
strongly correlated with the age at first intercourse (Figure, D) (correlation coefficient=0.4).
For women who had first sexual intercourse at younger ages (eg, at 10, 11, 12, 13, and 14
years), the median intervals between first sexual intercourse and first STI test were 4.9, 3.5,
2.1, 1.8, and 1.2 years, respectively.
COMMENT
Most women become sexually active during adolescence, and earlier age at first sexual
intercourse is associated with increased STI risk. The US Preventive Services Task Force
recommends screening women younger than 25 years for C trachomatis and N gonorrhoeae,
13,26 and the Centers for Disease Control and Prevention suggests annual screening for C
trachomatis for sexually active women within 1 year of first coitus and screening for N
gonorrhoeae for women at increased risk until age 26 years.12 However, neither group has
made evidence-based recommendations on the most appropriate starting age and the most
appropriate frequency of screening.14
To our knowledge, this research provides the first data on the timing of the initial and
subsequent STIs following the onset of sexual activity in a high-risk sample of urban young
women. Half of the study participants became infected within 2 years of first sexual
intercourse, with C trachomatis infection detected earlier than N gonorrhoeae and T
vaginalis infections(P<.001).Repeated STIs were common, and the time to reinfections
usually was very short, especially for C trachomatis. This is consistent with the results of
previous studies supporting relatively early rescreening following an initial STI, especially if
the index infection is due to C trachomatis.27 However, continuing surveillance may be
necessary because of the continuing high risk of infection even if the first rescreening test
result is negative.
The findings highlight the importance of early STI screening in urban adolescent women,
especially considering the minimal harm of screening.28 For example, our data show that
25% of young women will have their first STI within 1 year after first intercourse (Table 2).
Therefore, if screening starts within 1 year of first intercourse, a great majority (75%) of
young women will have the benefit of screening before acquiring their first STI.
Alternatively, our data can be used to support the beginning ages of screening in the absence
of information about prior sexual activity. For example, 25% of first infections with C
trachomatis, N gonorrhoeae, and T vaginalis occur at ages 15, 17, and 17 years, respectively
(Table 2). Therefore, beginning screening at age 15 years would bring benefit to more than
75% of the young women before acquiring the first infection. Similarly, our data can be used
to guide screening frequency. If we wish to screen at a time when no more than 25% of
reinfections have occurred with C trachomatis, N gonorrhoeae, and Tvaginalis, our
screening intervals would be 3.6, 6, and 4.8 months, respectively (Table 2). If the 10th
percentile is used, more aggressive screening for these organisms (in 2.4 months) would be
needed. Similar rescreening intervals have been suggested for an urban adult population.29
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Despite the current guidelines’ dependence on clinical determination of sexual activity, the
interval between first sexual intercourse and first STI test was especially prolonged for those
with earliest onset of first intercourse. For example, the median delay of the first STI test
was almost 5 years after the first coitus for those young women who reported first
intercourse at age 10 years. A wide range of factors may have contributed to delayed
screening, including vague language of the guidelines, patients’ deferral of appointments,
and misperception among some providers that STI risk begins at later ages. Statutory
requirement to report underage sexual activities may also discourage risk assessment.
Regardless, these data are consistent with findings that physicians fail to obtain sexual
history from a large proportion of adolescent patients.30,31 An important implication of
these findings is the need for renewed emphasis on training, skills, and incentives to conduct
such screenings by those who care for adolescent patients. Quality assurance standards such
as the Health Plan Employer Data and Information Set
(http://www.ncqa.org/tabid/892/Default.aspx) can serve as important reminders for
screening for sexual activity among young women, although the Health Plan Employer Data
and Information Set does not define sexual activity. Within the context of standards for
preventive health care for young women, perhaps a more specific and achievable national
health objective would be obtaining initial STI screening tests within 12 months of young
women’s first sexual intercourse, as our data suggest.
Intervals between first sexual intercourse and first STI appear to be different for the 3
organisms, which to our knowledge, has not been prospectively demonstrated among
adolescent women. This differential time to infection could at least in part be explained by
the organisms’ respective prevalence rates among the partner population. Previous studies
show that young age is associated with increased risk of C trachomatis infection, while older
age is associated with increased risk of T vaginalis infections.32,33 Cervicovaginal tissue
immaturity, cervical ectopy, or immunologic naivete are proposed as explanations for age-
related differences in C trachomatis infections.34 However, the same ordering of STI was
seen for each sexual intercourse onset cohort (data not shown). While the issue is beyond the
scope of the current article, there may be a need for a closer examination of the transmission
risks of these organisms. Whatever the explanation, these data lend more credence to current
emphasis on early C trachomatis screening among young women.
Our study focuses on a sample of urban adolescents at elevated STI risk, characterized by
early age at first coitus, multiple sexual partners, and high STI rates. The results may not be
readily generalizeable to suburban and rural youths or urban residents of higher
socioeconomic status. However, considering that inner-city residents of lower
socioeconomic status bear much of the disease burden of STI, such a focus is justified. The
research points to the need for future studies to examine the STI time patterns in other
groups. Second, the use of STI tests obtained from electronic medical records raises the
possibility that some tests were obtained for diagnostic evaluations rather than for routine
screening. To the extent that this is true, it would lead to an underestimate of the STI
incidence before the study period. Therefore, the actual occurrence of the first STI events
following the onset of sex could be sooner than what we reported, thus justifying an even
earlier starting age of screening. In this sense, our data represent a potentially more
conservative timeline of STI testing events in adolescent women.
Timely screening and treatment of STIs in women, particularly C trachomatis, decrease the
risk of complications resultingfromuntreatedinfection.35 To achieve such a goal, STI
screening should begin within a year after first intercourse. Furthermore, because of ongoing
high risk for subsequent infection, our study suggests the need for follow-up screening as
frequently as every 3 to 4 months. We recognize the many financial and practical barriers to
such intensive programs. Nevertheless, screening and treatment efforts based on evidence-
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based estimates of onset and level of risk will be the mainstay of prevention of STI
complications.
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Figure.
Distributions of age at first sexual intercourse (A), time from first sexual intercourse to first
diagnosis of sexually transmitted infection (STI) with Chlamydia trachomatis, Neisseria
gonorrhoeae, or Trichomonas vaginalis (B), time from initial STI to first reinfection (C),
and relationship between the age at first sexual intercourse and age at first STI test (D).
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Table 1
Demographic and Behavioral Characteristics of the Young Women’s Project Participants
Subject Characteristic Mean (SD)
Age at enrollment, y (range, 14–17 y) 15.3 (1.1)
African American ethnicity, No. (%) 344 (89.1)
Length of follow-up, y (range, 0–8.2 y) 3.2 (2.0)
No. of partners in the last 2 mo, reported at enrollment 1 (1)
No. of partners during lifetime, reported at enrollment [median] 3 (4) [2]
Age at first sexual intercourse, ya 14.2 (2.0)
 25th, 50th, 75th Percentiles 13, 14, 15
a
Age at first sex ascertained from interviews was accurate to the year.
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